title: Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?
abstract: OBJECTIVE
  To compare glucose and lipid metabolism parameters between drug-naïve first-episode psychosis (FEP) patients with a diagnosis of schizophrenia spectrum disorder and healthy controls matched for age, ethnicity, and gender.
  
  
  METHODS
  Baseline evaluations of fasting glucose and lipid metabolism parameters and the oral glucose tolerance test were performed with FEP patients (n=38), having no more than 10 days of cumulative exposure to antipsychotic medication, and normal community controls (n=36). Analysis of variance (ANOVA) was conducted to examine between group differences.
  
  
  RESULTS
  FEP patients did not show a higher prevalence of the precursors to diabetes (impaired fasting glucose, impaired glucose tolerance, insulin resistance), and no significant difference in beta-cell function or lipid profile measures, compared to healthy controls. FEP patients showed a higher waist to hip ratio compared to controls.
  
  
  CONCLUSIONS
  FEP patients having a schizophrenia spectrum disorder do not differ from healthy controls, in their baseline measures of glucose and lipid metabolites, nor in the prevalence of diabetes or its precursors, before (or close to) the onset of antipsychotic treatment.
authors.affiliation: Douglas Mental Health University Institute, Louis H. Lafontaine Hospital, Montreal, Canada.
authors.forename: Sarojini
authors.initials: S
authors.lastname: Sengupta
authors.forename: Maria A
authors.initials: MA
authors.lastname: Parrilla-Escobar
authors.forename: Ruby
authors.initials: R
authors.lastname: Klink
authors.forename: Ferid
authors.initials: F
authors.lastname: Fathalli
authors.lastname: Ying Kin Ng
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Stip
authors.forename: Trino
authors.initials: T
authors.lastname: Baptista
authors.forename: Ashok
authors.initials: A
authors.lastname: Malla
authors.forename: Ridha
authors.initials: R
authors.lastname: Joober
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism*; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D035061:Control Groups; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000378:metabolism; D005215:Fasting / Q000378:metabolism; D005260:Female; D018149:Glucose Intolerance / Q000097:blood / Q000175:diagnosis; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D050356:Lipid Metabolism; D008297:Male; D011446:Prospective Studies; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D014280:Triglycerides / Q000097:blood / Q000378:metabolism; D049629:Waist-Hip Ratio
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D007328:Insulin; D014280:Triglycerides; D002784:Cholesterol